Navigation Links
Study identifies a likely key driver of colorectal cancer development and progression
Date:4/14/2014

COLUMBUS, Ohio A new study identifies a molecule that is a probable driving force in colorectal cancer and suggests that the molecule could be an important target for colorectal cancer treatment and a valuable biomarker of tumor progression.

The study of microRNA-135b (miR-135b) in two animal models and human tumors was published in the journal Cancer Cell and was led by researchers at The Ohio State University Comprehensive Cancer Center Arthur G. James Cancer Hospital and Richard J. Solove Research Institute (OSUCCC James) and at the University of Glasgow in the United Kingdom.

The researchers demonstrate that miR-135b is present at abnormally high levels in both mouse and human colorectal (CRC) tumors. The overexpression can be induced by the mutations in either well-known oncogenes or tumor-suppressor genes that frequently occur in CRC, the researchers say.

"We found that miR-135b is up-regulated in both sporadic and inflammatory bowel disease-associated colorectal cancer, and that its up-regulation is associated with tumor stage and poor clinical outcome," says principal investigator Carlo M. Croce, MD, chair of molecular virology, immunology and medical genetics, and director of Human Cancer Genetics at Ohio State and the OSUCCC James.

"Our findings provide proof-of-principle that anti-miR-135b has significant therapeutic potential in colorectal cancer treatment," says Croce, who is also the John W. Wolfe Chair in Human Cancer Genetics.

For this study, Croce and his collaborators used a CRC mouse model based on loss of a tumor suppressor and a model based on inflammation and oncogene activation; human tumors from a cohort of sporadic CRC and inflammatory-bowel-disease associated CRC; human and animal cell lines and data from The Cancer Genome Atlas.

Key findings included:

  • MiR-135b up-regulation occurs in both sporadic and inflammatory bowel disease-associated CRC, and it is associated with tumor stage and poor clinical outcome;
  • Loss of the APC gene, deregulation of the PTEN/PI3K pathway and over-expression of the SRC oncogene all trigger miR-135b over-expression;
  • Artificial miR-135b over-expression increases cell proliferation and reduces apoptosis, as occurs with APC loss or PI3K or SRC activation.
  • Delivering anti-miR-135b in an inflammation-related CRC mouse model affected proliferation and apoptosis, resulting in reduced tumor number and size.


'/>"/>

Contact: Darrell E. Ward
Darrell.Ward@osumc.edu
614-293-3737
Ohio State University Wexner Medical Center
Source:Eurekalert

Related medicine news :

1. Study gives high marks to NC Pre-K program
2. Proteomics International biomarker study closer to a CDx test for diabetic kidney disease
3. Study links domestic abuse to mental health problems in new mothers
4. Empowerment program greatly decreases incidence of rape, Stanford/Packard-led study finds
5. Lipid levels during prenatal brain development impact autism: York U study
6. ED dental care treatment raises access, cost issues for policymakers, Rutgers study finds
7. $2.5 million Defense Department grant funds gene therapy study for Lou Gehrigs disease
8. Study finds link between childs obesity and cognitive function
9. Study reveals animal research bias in experimentation oversight committee membership
10. Fruitfly study: Epilepsy drug target implications for sleep disruption in brain disorders
11. Obesity primes the colon for cancer, according to NIH study
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/22/2017)... CANADA (PRWEB) , ... July 22, 2017 , ... ... offer patients with irreparable rotator cuff repairs the opportunity to return to sports ... the American Orthopaedic Society for Sports Medicine’s Annual Meeting in Toronto, ...
(Date:7/21/2017)... ... ... The Ellis Agency, an eastern Georgie provider of insurance management and financial ... event with the goal of bringing in support for epilepsy patients in the greater ... recently launched a charity campaign of her own by donating her birthday to the ...
(Date:7/21/2017)... Long Grove, Ill. (PRWEB) , ... July 21, 2017 , ... ... Air & Fabric Liquid eco-friendly odor-control solution for colleges and universities at the ... to safely and effectively eliminate severe cannabis and tobacco smoke odors without the use ...
(Date:7/21/2017)... (PRWEB) , ... July 21, 2017 , ... The Margarian ... falsely advertising the contents of its ginger ale for allegedly containing no ginger. Dr. ... Dr. Pepper Snapple Group, Inc., plaintiff Gegham Margaryan alleges Canada Dry Ginger Ale claims ...
(Date:7/21/2017)... ... July 21, 2017 , ... “Kids aren't born knowing ... tie their shoes,” says Suzanne Tucker, Founder of St. Louis-based positive education company Generation ... launches on Kickstarter on Monday, July 21st. , The kit uses colorful, engaging ...
Breaking Medicine News(10 mins):
(Date:7/13/2017)... July 13, 2017  New York City-based market research firm ... should be aware of.  From new products to new costs, ... in a recently completed study, Potential Pipeline Disruptors . ... 1.  Age-Driven Growth - True Impact ... aware of the impact the growing population and, to a ...
(Date:7/11/2017)... , July 11, 2017  The global market ... revenues of approximately $394.1 million in 2016.  Although in ... of solid growth, in particular as a result of ... practice, and the recent introduction of a significant number ... for less-invasive testing of tumor biomarkers to guide treatment ...
(Date:7/10/2017)... Md. , July 10, 2017 The ... non-animal test methods, is the recipient of a VITROCELL® ... the PETA International Science Consortium. The device, which is ... used to expose human lung cells to airborne test ... IIVS will use the VITROCELL® system for testing combustible ...
Breaking Medicine Technology: